PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Lichtenegger, F.S.* ; Schnorfeil, F.M.* ; Rothe, M.* ; Deiser, K.* ; Altmann, T.* ; Bücklein, V.L.* ; Köhnke, T.* ; Augsberger, C.* ; Konstandin, N.P.* ; Spiekermann, K.* ; Moosmann, A. ; Boehm, S.* ; Boxberg, M.* ; Heemskerk, M.H.M.* ; Goerlich, D.* ; Wittmann, G.* ; Wagner, B.* ; Hiddemann, W.* ; Schendel, D.J.* ; Kvalheim, G.* ; Bigalke, I.* ; Subklewe, M.*

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: Results of a phase I trial.

Clin. Transl. Immunology 9:e1117 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Objectives Innovative post-remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti-leukaemic immune responses.Methods We conducted a first-in-human phase I study using TLR7/8-matured DCs transfected with RNA encoding the two AML-associated antigens WT1 and PRAME as well as CMVpp65. AML patients in CR at high risk of relapse were vaccinated 10x over 26 weeks.Results Despite heavy pretreatment, DCs of sufficient number and quality were generated from a single leukapheresis in 11/12 cases, and 10 patients were vaccinated. Administration was safe and resulted in local inflammatory responses with dense T-cell infiltration. In peripheral blood, increased antigen-specific CD8(+) T cells were seen for WT1 (2/10), PRAME (4/10) and CMVpp65 (9/10). For CMVpp65, increased CD4(+) T cells were detected in 4/7 patients, and an antibody response was induced in 3/7 initially seronegative patients. Median OS was not reached after 1057 days; median RFS was 1084 days. A positive correlation was observed between clinical benefit and younger age as well as mounting of antigen-specific immune responses.Conclusions Administration of TLR7/8-matured DCs to AML patients in CR at high risk of relapse was feasible and safe and resulted in induction of antigen-specific immune responses. Clinical benefit appeared to occur more likely in patients The study was registered at on 17 October 2012 (NCT01734304) and at (EudraCT-Number 2010-022446-24) on 10 October 2013.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.464
1.689
6
12
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Myeloid Leukaemia ; Cancer Vaccines ; Clinical Trials ; Dendritic Cell Vaccination ; Immunotherapy; Testis Antigen-expression; T-lymphocyte Responses; Immunotherapy; Vaccination; Induction; Generation
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 2050-0068
e-ISSN 2050-0068
Zeitschrift Clinical and translational immunology
Quellenangaben Band: 9, Heft: 3, Seiten: , Artikelnummer: e1117 Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Gene Vector (AGV)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-501500-001
DOI 10.1002/cti2.1117
WOS ID WOS:000522447300007
Scopus ID 85082424877
PubMed ID 32153780
Erfassungsdatum 2020-04-20
[➜Korrektur melden]